Fresenius Medical Care AG and Co. KGaA (FMS) |
| 23.015 -0.255 (-1.1%) 08-28 10:42 |
| Open: | 23.16 |
| High: | 23.24 |
| Low: | 22.91 |
| Volume: | 227,570 |
| Market Cap: | 12,362(M) |
| PE Ratio: | 8.65 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Care Facilities |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 26.42 |
| Resistance 1: | 25.13 |
| Pivot price: | 23.59 |
| Support 1: | 23.03 |
| Support 2: | 19.17 |
| 52w High: | 27.64 |
| 52w Low: | 20.02 |
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
| EPS | 1.940 |
| Book Value | 27.290 |
| PEG Ratio | 0.82 |
| Gross Profit | 9.620 |
| Profit Margin (%) | 4.83 |
| Operating Margin (%) | 10.77 |
| Return on Assets (ttm) | 4.0 |
| Return on Equity (ttm) | 8.5 |
Mon, 24 Aug 2026
Major Fresenius Medical Care (NYSE: FMS) investor moves to sell block of shares - Stock Titan
Fri, 21 Aug 2026
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Share Price Passes Above 200 Day Moving Average - Time to Sell? - MarketBeat
Wed, 19 Aug 2026
Fresenius Medical Care stock holds steady as mid-2026 trading data align with recent NYSE levels. - Ad-hoc-news.de
Wed, 05 Aug 2026
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand - Yahoo Finance
Tue, 04 Aug 2026
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Trading Down 6% - Time to Sell? - MarketBeat
Mon, 03 Aug 2026
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Announces Earnings Results - MarketBeat
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |